Rick T van Uum1, Roderick P Venekamp2, Clémence T B Pasmans2, G Ardine de Wit2,3, Alies Sjoukes2, Alma C van der Pol2, Roger A M J Damoiseaux2, Anne G M Schilder2,4,5. 1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University Utrecht, P.O. Box 85500, 3508, GA, Utrecht, The Netherlands. R.T.vanUum-2@umcutrecht.nl. 2. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University Utrecht, P.O. Box 85500, 3508, GA, Utrecht, The Netherlands. 3. Centre for Nutrition, Prevention and Healthcare, National Institute of Public Health and the Environment, Bilthoven, The Netherlands. 4. evidENT, Ear Institute, University College London, London, UK. 5. National Institute for Health Research, University College London Hospitals Biomedical Research Centre, London, UK.
Abstract
BACKGROUND:Acute otitis media (AOM) is among the most common paediatric conditions managed in primary care. Most recent estimates of the cost of AOM date from a decade ago and lack a full societal perspective. We therefore explored the societal cost of childhood AOM in the Netherlands within the setting of a trial comparing the effectiveness of an intervention aimed at educating general practitioners (GPs) about pain management in AOM compared to usual care. METHODS: Economic analysis alongside a cluster randomised controlled trial conducted between February 2015 and May 2018 in 37 practices (94 GPs). In total, 224 children with AOM were included of which 223 (99%) completed the trial (intervention: n = 94; control: n = 129). The cost of AOM due to health care costs, patient and family costs, and productivity losses by parent caregivers were retrieved from study diaries and primary care electronic health records, during 28-day follow-up. We calculated mean cost (€ and $) per AOM episode per patient with standard deviations (SD, in €) regardless of study group assignment because there was no clinical effect of the trial intervention. In sensitivity analysis, we calculated cost in the intervention and usual care group, after exclusion of extreme outliers. RESULTS:Mean total AOM cost per patient were €565.93 or $638.78 (SD €1071.01); nearly 90% of these costs were due to productivity losses experienced by parents. After exclusion of outliers, AOM cost was €526.70 or $594.50 (SD €987.96) and similar in the intervention and usual care groups: €516.10 or $582.53 (SD €949.69) and €534.55 or $603.36 (SD €920.55) respectively. CONCLUSIONS: At €566 or $639 per episode, societal cost of AOM is higher than previously known and mainly driven by productivity losses by children's parents. Considering its high incidence, AOM poses a significant economic burden that extends beyond direct medical costs. TRIAL REGISTRATION: Netherlands Trial Register no. NTR4920: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4920 .
RCT Entities:
BACKGROUND:Acute otitis media (AOM) is among the most common paediatric conditions managed in primary care. Most recent estimates of the cost of AOM date from a decade ago and lack a full societal perspective. We therefore explored the societal cost of childhood AOM in the Netherlands within the setting of a trial comparing the effectiveness of an intervention aimed at educating general practitioners (GPs) about pain management in AOM compared to usual care. METHODS: Economic analysis alongside a cluster randomised controlled trial conducted between February 2015 and May 2018 in 37 practices (94 GPs). In total, 224 children with AOM were included of which 223 (99%) completed the trial (intervention: n = 94; control: n = 129). The cost of AOM due to health care costs, patient and family costs, and productivity losses by parent caregivers were retrieved from study diaries and primary care electronic health records, during 28-day follow-up. We calculated mean cost (€ and $) per AOM episode per patient with standard deviations (SD, in €) regardless of study group assignment because there was no clinical effect of the trial intervention. In sensitivity analysis, we calculated cost in the intervention and usual care group, after exclusion of extreme outliers. RESULTS: Mean total AOM cost per patient were €565.93 or $638.78 (SD €1071.01); nearly 90% of these costs were due to productivity losses experienced by parents. After exclusion of outliers, AOM cost was €526.70 or $594.50 (SD €987.96) and similar in the intervention and usual care groups: €516.10 or $582.53 (SD €949.69) and €534.55 or $603.36 (SD €920.55) respectively. CONCLUSIONS: At €566 or $639 per episode, societal cost of AOM is higher than previously known and mainly driven by productivity losses by children's parents. Considering its high incidence, AOM poses a significant economic burden that extends beyond direct medical costs. TRIAL REGISTRATION: Netherlands Trial Register no. NTR4920: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4920 .
Authors: A Rogier T Donders; Geert J M G van der Heijden; Theo Stijnen; Karel G M Moons Journal: J Clin Epidemiol Date: 2006-07-11 Impact factor: 6.437
Authors: Allan S Lieberthal; Aaron E Carroll; Tasnee Chonmaitree; Theodore G Ganiats; Alejandro Hoberman; Mary Anne Jackson; Mark D Joffe; Donald T Miller; Richard M Rosenfeld; Xavier D Sevilla; Richard H Schwartz; Pauline A Thomas; David E Tunkel Journal: Pediatrics Date: 2013-02-25 Impact factor: 7.124
Authors: José A Suaya; Bradford D Gessner; Shirley Fung; Scott Vuocolo; John Scaife; David L Swerdlow; Raúl E Isturiz; Adriano G Arguedas Journal: Vaccine Date: 2018-10-24 Impact factor: 3.641
Authors: Tal Marom; Alai Tan; Gregg S Wilkinson; Karen S Pierson; Jean L Freeman; Tasnee Chonmaitree Journal: JAMA Pediatr Date: 2014-01 Impact factor: 16.193
Authors: Rick T van Uum; Roderick P Venekamp; Alies Sjoukes; Alma C van de Pol; G Ardine de Wit; Anne G M Schilder; Roger A M J Damoiseaux Journal: Trials Date: 2018-09-17 Impact factor: 2.279
Authors: Rick T van Uum; Roderick P Venekamp; Nicolaas Pa Zuithoff; Alies Sjoukes; Alma C van de Pol; Anne Gm Schilder; Roger Amj Damoiseaux Journal: Br J Gen Pract Date: 2020-10-01 Impact factor: 5.386